These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27749327)

  • 41. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Promising immunotherapy for prostate cancer.
    Henegan JC; Sonpavde G
    Expert Opin Biol Ther; 2018 Feb; 18(2):109-120. PubMed ID: 29231062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combining immunotherapy and radiation for prostate cancer.
    Finkelstein SE; Salenius S; Mantz CA; Shore ND; Fernandez EB; Shulman J; Myslicki FA; Agassi AM; Rotterman Y; DeVries T; Sims R
    Clin Genitourin Cancer; 2015 Feb; 13(1):1-9. PubMed ID: 25450032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F
    Cells; 2020 Sep; 9(9):. PubMed ID: 32911806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune response to sipuleucel-T in prostate cancer.
    Thara E; Dorff TB; Averia-Suboc M; Luther M; Reed ME; Pinski JK; Quinn DI
    Cancers (Basel); 2012 Apr; 4(2):420-41. PubMed ID: 24213318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy of Prostate Cancer: Facts and Hopes.
    Bilusic M; Madan RA; Gulley JL
    Clin Cancer Res; 2017 Nov; 23(22):6764-6770. PubMed ID: 28663235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of metastatic castration-resistant prostate cancer: recent advances.
    Mukherji D; Eichholz A; De Bono JS
    Drugs; 2012 May; 72(8):1011-28. PubMed ID: 22621691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC; Hansen AR
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.
    Gulley JL; Madan RA; Pachynski R; Mulders P; Sheikh NA; Trager J; Drake CG
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Immunotherapy for metastatic prostate cancer: do we really need this?].
    Heidenreich A
    Urologe A; 2012 Jan; 51(1):32-8. PubMed ID: 22258374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging role of immunotherapy in the management of prostate cancer.
    Slovin SF
    Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From bench to bedside: immunotherapy for prostate cancer.
    Tse BW; Jovanovic L; Nelson CC; de Souza P; Power CA; Russell PJ
    Biomed Res Int; 2014; 2014():981434. PubMed ID: 25276838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy in the treatment of advanced prostate cancer.
    Djavan B; Nelson K; Kazzazi A; Bruhn A; Sadri H; Gomez-Pinillos A; Ferrari AC
    Can J Urol; 2011 Oct; 18(5):5865-74. PubMed ID: 22018147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgen deprivation and immunotherapy for the treatment of prostate cancer.
    Gamat M; McNeel DG
    Endocr Relat Cancer; 2017 Dec; 24(12):T297-T310. PubMed ID: 28814451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy for prostate cancer: recent developments and future challenges.
    Schweizer MT; Drake CG
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):641-55. PubMed ID: 24477411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.